MBX 2109, A Once-Weekly Parathyroid Hormone Replacement Therapy Prodrug: Phase 1, First-In-Human, Randomized Trial
The Journal of Clinical Endocrinology & Metabolism · 17.03.2025 · 110 (4) · 940-950
DOI: 10.1210/clinem/dgae808 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, online erschienen am 22.11.2024. Verfasst von Patricia Carney und 4 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Operations, MBX Biosciences Inc, Carmel, IN 46032, USA. Hauptthemen laut MEDLINE: Prodrugs, Parathyroid Hormone, Hormone Replacement Therapy, Hypoparathyroidism. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: MBX Biosciences, Inc.
Abstract (Originalsprache)
Context
Hypoparathyroidism denotes parathyroid hormone (PTH) deficiency and impaired mineral metabolism. MBX 2109, a novel prodrug yielding a biologically active PTH peptide agonist (PTH[1-32], extended by a fatty acylated Lys33), is being developed as a long-acting, once-weekly PTH replacement therapy.
Objective
Here, we report the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of MBX 2109 in healthy volunteers.
Methods
This phase 1, randomized, double-blind, placebo-controlled, multiple ascending-dose study (NCT05158335) enrolled healthy adults, who were randomly assigned 4:1 to receive MBX 2109 (200, 400, 600, and 900 μg; n = 8) or placebo (n = 2) by subcutaneous administration once weekly for 4 doses (days 1, 8, 15, and 22). The primary end point was safety and tolerability. Key secondary end points were PK and PD.
Results
Overall, 40 participants (MBX 2109 n = 32, placebo n = 8) were randomly assigned (mean age, 43.3 years; 22.5% female). Treatment-emergent adverse events (TEAEs) occurred in 50% to 88% of MBX 2109 groups and in 25% of placebo participants. In the MBX 2109 groups, no severe or serious TEAEs were observed. Injection-site reaction was the most common treatment-related TEAE. The half-lives were 79 to 95 hours for MBX 2109 and 184 to 213 hours for the fatty-acylated biologically active PTH peptide, which showed dose- and time-dependent exposure increases.
Conclusion
The sustained-action PTH prodrug MBX 2109 was well tolerated with no unexpected, off-target safety issues. The long half-life and flat exposure profile of MBX 2109's biologically active PTH agonist supports once-weekly administration. MBX 2109 doses were identified for future studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical Operations, MBX Biosciences Inc, Carmel, IN 46032, USA.
- Gordon Cutler Consultancy, LLC, Deltaville, VA 23043, USA.
- Clinical Development, MBX Biosciences Inc, Carmel, IN 46032, USA.
- Department of Chemistry, Indiana University, Bloomington, IN 47405, USA.
ORCID-Profile: Patricia Carney, Gordon B Cutler, Kristi Schneider, Fa Zhang, Richard DiMarchi
Förderung
- MBX Biosciences, Inc
Zitieren
APA
Carney, P., Cutler, G. B., Schneider, K., Zhang, F., & DiMarchi, R. (2025). MBX 2109, A Once-Weekly Parathyroid Hormone Replacement Therapy Prodrug: Phase 1, First-In-Human, Randomized Trial. The Journal of Clinical Endocrinology & Metabolism, 110(4), 940-950. https://doi.org/10.1210/clinem/dgae808
Vancouver
Carney P, Cutler GB, Schneider K, Zhang F, DiMarchi R. MBX 2109, A Once-Weekly Parathyroid Hormone Replacement Therapy Prodrug: Phase 1, First-In-Human, Randomized Trial. The Journal of Clinical Endocrinology & Metabolism. 2025;110(4):940-950. doi:10.1210/clinem/dgae808
BibTeX
@article{Carney2025,
author = {Carney, Patricia and Cutler, Gordon B and Schneider, Kristi and Zhang, Fa and DiMarchi, Richard},
title = {MBX 2109, A Once-Weekly Parathyroid Hormone Replacement Therapy Prodrug: Phase 1, First-In-Human, Randomized Trial},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2025},
volume = {110},
number = {4},
pages = {940--950},
doi = {10.1210/clinem/dgae808}
}
EUVIMED